shengnuo biotechnology: Leading domestic peptide drug company Net profit attributable to the parent rose 83.9% in the third quarter
On October 28, shengnuo biotechnology (688117.SH) disclosed the third quarterly report for 2021. During the reporting period, the company achieved revenue of 85,482,900 yuan and realized net profit attributable to the parent of 19,024,900 yuan, an increase of 83.9% year-on-year. At the same time, in the first three quarters of this year, the company’s revenue and net profit attributable to the parent showed an upward trend. Among them, operating income was RMB 279,121,300, a year-on-year increase of 3.03%; net profit attributable to the parent was RMB 43,033,900, a year-on-year increase of 3.31%.
As a leading domestic peptide drug company, the company has always established a brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials. At the same time, enter the preparation market to form the main business of peptide innovative drug pharmaceutical research services and peptide product customized production services parallel to the production and sales of peptide APIs and preparations, and strengthen the company’s competitive advantage in the peptide field through coordinated development between businesses , The formation of performance growth points.
The peptide drug market is on the rise
The company has abundant product reserves and significant pipeline advantages
In recent years, peptide drugs have become an important direction for new drug research and development at home and abroad. According to data from China Business Intelligence Network, although my country’s peptide drug market started late, it has developed rapidly. Sales rose from 24.19 billion yuan in 2016 to 35.78 billion yuan in 2020, with a growth rate of over 15% during the period and is expected to be 2021 The annual sales of peptide drugs in China will reach 38.71 billion yuan. With the introduction of China’s policies to encourage the research and development of innovative drugs and promote the consistency evaluation of generic drugs, it is expected that more innovative peptide drugs and peptide generic drugs with significant clinical effects will be approved for marketing in the future, which will further expand the market for peptide drugs in China.
It can be said that under the broader development prospects of the industry, related companies are also expected to continue to expand the market space.
It is understood that, as one of the earliest established professional peptide drug manufacturers in China, after years of experience in peptide drug research and development, production and industrialization development, Senno Bio has become one of the few domestic peptide drug fields with peptide API and preparation research and development, The company that produces and sells the entire industry chain is one of the most powerful peptide drug synthesis and production technology platforms in China, and it is also one of the market competitors in the global regulated market peptide generic drug industry chain.
At present, the company’s main product lines cover multiple therapeutic areas such as digestive system, immune system diseases, anti-tumor, chronic hepatitis B, diabetes, and obstetrics. It is one of the domestic peptide drug manufacturers with a relatively complete product line. The latest data shows that as of the end of June 2021, the company has bivalrudine, eptifibatide, icatibant, liraglutide, octreotide acetate, ziconotide, teriparatide, 8 Ganirec products have been registered and activated by the US DMF.
In the domestic market, the company has obtained 19 domestic drug registration approval numbers or domestic filings for peptide drugs, including 8 peptide APIs and 12 peptide preparation specifications. They are two domestic preparations of enfuvirtide and carbetocin. The first imitation enterprise of the product. In addition, the company has more than ten peptide drug products in the research and development stage, and the product line is expected to be further expanded and enriched in the future.
Has a number of core technologies
R&D and production services continue to work hard
At present, the company has mastered a number of core technologies required for the production of peptide drugs, and is one of the few domestic companies that can produce multiple peptide APIs on a large scale. Through independent research and development, he has mastered the synthesis and modification of long-chain peptide coupling technology, monosulfide cyclic peptide large-scale production technology, multiple pairs of disulfide cyclic peptide synthesis technology, fragment condensation technology, pegylation modification technology, fatty acid modification technology, etc. This kind of independent core technology has successfully solved the technical bottleneck of the large-scale production of multiple peptide API varieties.
The company applies various core technologies to varying degrees in the company’s peptide API and preparation R&D, peptide innovative drug pharmaceutical research services, and peptide product customized production services, combined with rich experience in process design High, to ensure high purity and total yield after purification, effectively reduce production costs, solve the problem of batch production of a number of bulk drug products, and realize the commercial application of drugs.
As of the end of June 2021, the company has 32 invention patents (1 of which also obtained international patents) and a large number of non-patent technologies. At the same time, the company has a professional and stable scientific research team with rich experience in R&D and industrialization of process technology in the field of chemical synthesis of peptides.
Significant advantages in the integration of the entire industry chain
Products are exported to many countries and regions
At present, domestic companies engaged in peptide drugs and peptide-related products are limited by R&D technology, capital, process level, production line equipment, raw materials, etc., and most of them focus on a certain link in the platform industry chain.
In comparison, for peptide drugs, it satisfies the need for the integration of R&D and production from initial materials to APIs, that is, the full-process industrial chain of “customized peptides-pharmaceutical research-APIs-preparations”, and all links have profit opportunities. , The preparation link is at the top of the industrial value chain.
shengnuo biotechnology has a full-process R&D pipeline and a full-industry chain platform for peptide APIs and preparations, and can provide pharmaceutical research for innovative peptide drugs and generic drugs from process route design to small-scale, pilot-scale, process verification and quality research. Services, as well as the entire chain of customized production services for APIs and preparation products required for drug R&D and commercial production, covering the complete drug development cycle from drug discovery, preclinical research, to clinical trials and marketing.
In addition, the company has many years of industrialization experience in the field of peptides, and has achieved large-scale production of multiple peptide APIs. Its quality standards have been recognized by customers at home and abroad, and its products have been exported to many countries and regions including the United States and the European Union. , Which can meet the needs of rapid, large-volume, high-quality peptide synthesis, and at the same time, the production cost has a comparative advantage in competition.